CN117801114A - 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途 - Google Patents

抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途 Download PDF

Info

Publication number
CN117801114A
CN117801114A CN202311813323.8A CN202311813323A CN117801114A CN 117801114 A CN117801114 A CN 117801114A CN 202311813323 A CN202311813323 A CN 202311813323A CN 117801114 A CN117801114 A CN 117801114A
Authority
CN
China
Prior art keywords
seq
amino acid
variable region
antibody variable
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311813323.8A
Other languages
English (en)
Chinese (zh)
Inventor
井川佑理
大仓有生
沟吕木晓彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN117801114A publication Critical patent/CN117801114A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202311813323.8A 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途 Pending CN117801114A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020-157873 2020-09-18
JP2020157873 2020-09-18
PCT/JP2021/034240 WO2022059766A1 (en) 2020-09-18 2021-09-17 Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease
CN202180061976.8A CN116096757B (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180061976.8A Division CN116096757B (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途

Publications (1)

Publication Number Publication Date
CN117801114A true CN117801114A (zh) 2024-04-02

Family

ID=80739984

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202180061976.8A Active CN116096757B (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
CN202311813323.8A Pending CN117801114A (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
CN202311818773.6A Pending CN117801115A (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202180061976.8A Active CN116096757B (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311818773.6A Pending CN117801115A (zh) 2020-09-18 2021-09-17 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途

Country Status (16)

Country Link
US (2) US11739153B2 (enExample)
EP (1) EP4214236A4 (enExample)
JP (2) JP7147030B2 (enExample)
KR (2) KR20230116942A (enExample)
CN (3) CN116096757B (enExample)
AR (1) AR123537A1 (enExample)
AU (1) AU2021343008B2 (enExample)
CA (1) CA3192661A1 (enExample)
CL (1) CL2023000765A1 (enExample)
CO (1) CO2023003681A2 (enExample)
CR (1) CR20230166A (enExample)
IL (1) IL301326A (enExample)
MX (1) MX2023002191A (enExample)
PE (1) PE20231208A1 (enExample)
TW (2) TW202402804A (enExample)
WO (1) WO2022059766A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020204054A1 (en) * 2019-04-01 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5 antibody
TW202402804A (zh) 2020-09-18 2024-01-16 日商中外製藥股份有限公司 抗hla-dq2.5抗體及其用於治療乳糜瀉的用途
KR20240082388A (ko) * 2021-10-08 2024-06-10 추가이 세이야쿠 가부시키가이샤 프리필드 시린지 제제의 조제 방법
AU2022361874A1 (en) * 2021-10-08 2024-04-11 Chugai Seiyaku Kabushiki Kaisha Drug formulation of anti-hla-dq2.5 antibody

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
MXPA03009313A (es) 2001-04-12 2004-11-12 Academish Ziekenhuis Leiden Metodos y medios para uso de receptores de celulas t restringidos por hla-dq y peptidos derivados de prolamina unidos a hla-dq.
SG10201402265YA (en) 2008-02-07 2014-08-28 Amgen Inc Stabilized protein compositions
AU2013204429B9 (en) 2008-11-30 2017-01-05 Immusant, Inc. Compositions and methods for treatment of celiac disease
WO2010141658A1 (en) 2009-06-04 2010-12-09 The Regent Of The University Of Colorado Therapeutic compositions and methods for the prevention of autoimmune diseases
WO2012017003A1 (en) 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein
EP2787078B1 (en) * 2011-10-31 2019-05-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
WO2016202805A2 (en) 2015-06-15 2016-12-22 Consejo Superior De Investigaciones Científicas (Csic) Targeting of prolamin by rnai in bread wheat
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
JP7162607B2 (ja) 2017-02-27 2022-10-28 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５／８抗体およびセリアック病の治療のためのその使用
JP7299212B2 (ja) * 2017-10-03 2023-06-27 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５抗体
GB201802338D0 (en) 2018-02-13 2018-03-28 Univ Oslo Antigen binding proteins
WO2020204054A1 (en) * 2019-04-01 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5 antibody
TW202402804A (zh) 2020-09-18 2024-01-16 日商中外製藥股份有限公司 抗hla-dq2.5抗體及其用於治療乳糜瀉的用途

Also Published As

Publication number Publication date
JP2022051553A (ja) 2022-03-31
WO2022059766A1 (en) 2022-03-24
KR20220153469A (ko) 2022-11-18
AR123537A1 (es) 2022-12-14
PE20231208A1 (es) 2023-08-17
EP4214236A1 (en) 2023-07-26
CN116096757A (zh) 2023-05-09
CR20230166A (es) 2023-05-31
AU2021343008A9 (en) 2024-10-10
US20220089743A1 (en) 2022-03-24
TW202402804A (zh) 2024-01-16
JP7147030B2 (ja) 2022-10-04
MX2023002191A (es) 2023-03-03
AU2021343008A1 (en) 2023-06-01
KR102559128B1 (ko) 2023-07-24
AU2021343008B2 (en) 2025-11-13
CO2023003681A2 (es) 2023-04-05
TWI820484B (zh) 2023-11-01
JP2022172276A (ja) 2022-11-15
EP4214236A4 (en) 2024-10-30
CA3192661A1 (en) 2022-03-24
US11739153B2 (en) 2023-08-29
CN116096757B (zh) 2024-01-12
CN117801115A (zh) 2024-04-02
CL2023000765A1 (es) 2023-11-03
IL301326A (en) 2023-05-01
TW202229345A (zh) 2022-08-01
US20230357408A1 (en) 2023-11-09
KR20230116942A (ko) 2023-08-04

Similar Documents

Publication Publication Date Title
JP7592050B2 (ja) 抗ｈｌａ－ｇ抗体とその使用
EP3215532B1 (en) Anti-tim3 antibodies and methods of use
JP7141336B2 (ja) 抗ミオスタチン抗体および使用方法
CN116096757B (zh) 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
JP2025038092A (ja) 抗ｈｌａ－ｄｑ２．５抗体
TW202333781A (zh) 抗ｈｌａ－ｄｑ２﹒５抗體製劑
KR102614250B1 (ko) 항hla-dq2.5 항체의 제제
HK40084713A (en) Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease
CN118369115A (zh) 抗hla-dq2.5抗体的药物制剂
HK40084713B (zh) 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
HK40062978A (en) Anti-hla-dq2.5 antibody

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101674

Country of ref document: HK